Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01420861 · ClinicalTrials.gov registry record · Phase 2
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
A Phase 2 study, sponsored by GTx.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01420861 is a Phase 2 study that was terminated before completion, run by GTx. The registered enrollment target is 18 participants.
The verdict
NCT01420861, a Phase 2 study, was terminated before completion, sponsored by GTx.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response and Serum PSA progression)
Interventions
- DRUG GTx-758
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01420861
The ClinicalTrials.gov registry entry for NCT01420861 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GTx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GTx-758 is the first listed.
NCT01420861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01420861 about?
NCT01420861 is a clinical study titled "GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer". The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response and Serum PSA progression)
What is the current status of trial NCT01420861?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2011-09. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01420861?
The interventions under investigation include: GTx-758 (DRUG).
Who is sponsoring clinical trial NCT01420861?
This trial is sponsored by GTx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.